I should never have posted the “waiting for Godot” joke, that thing has spread across the bulletin boards.
The fact is, things are happening and we get closer and closer every day. That we are no longer at .14 in fact says that the market took notice of substantial progress. That we hit $2.51, was also acknowledgment by the market that news is ahead. That the price fluctuates is a fact of summer and an expected lull in trading volumes and news this time of year.
No event has occurred to suggest that the reveal is not ahead. And in fact, BiopharmIQ on Twitter has provided a reasonable likely estimate of the time of such data to arrive, and they are an objective, unconnected professional publisher that provides such estimates across the pharmaceutical industry.
Plus, we have seen the updated SAP info on the European clinical trial sites, we know things continue to progress, and we have seen a barrage of presentations by Dr. Liau, to doctors across the country generally about the trial process and what needs to be done to shape future trials as they seek to do similar things with this trial. This will likely be a very influential trial regarding future immunotherapy trials regardless of the results, given how much has been learned.
Lastly, we have been updated on the Sawston progress and we know that revenues will be anticipated to stream from that progress as soon as possible, once the new production facilities come online for real, even before any potential
approval.
Hard to say we are not seeing immense progress that absolutely suggests that the road ahead has a few major milestones and it all suggests that progress is indeed being made with determination. We know the unblinded results are difficult to dismiss and a number of third party studies have made reference to the 2017/18 publication of those interim blinded results with positive reference and suggestions.
So no, I don’t see what you’re saying.
News 
Market Data 
Discover 
AI
